Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Up 25.2% in April


Share on StockTwits

Abeona Therapeutics Inc (NASDAQ:ABEO) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 6,110,000 shares, an increase of 25.2% from the March 31st total of 4,880,000 shares. Based on an average trading volume of 3,810,000 shares, the short-interest ratio is presently 1.6 days.

In other news, CAO Edward Carr sold 35,000 shares of the stock in a transaction dated Monday, April 5th. The stock was sold at an average price of $1.80, for a total value of $63,000.00. Following the completion of the sale, the chief accounting officer now owns 226,291 shares in the company, valued at $407,323.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Todd Wider sold 321,345 shares of the company’s stock in a transaction that occurred on Thursday, February 18th. The stock was sold at an average price of $2.34, for a total value of $751,947.30. In the last three months, insiders have sold 742,199 shares of company stock valued at $1,838,485. 19.10% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Credit Suisse AG acquired a new position in Abeona Therapeutics in the fourth quarter worth approximately $27,000. WealthTrust Axiom LLC acquired a new stake in Abeona Therapeutics during the 1st quarter worth about $35,000. Virtu Financial LLC acquired a new position in shares of Abeona Therapeutics in the third quarter worth about $38,000. Wells Fargo & Company MN raised its holdings in shares of Abeona Therapeutics by 26.9% during the fourth quarter. Wells Fargo & Company MN now owns 80,942 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 17,168 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Abeona Therapeutics by 20.5% in the 4th quarter. Rhumbline Advisers now owns 89,874 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 15,299 shares in the last quarter. Institutional investors and hedge funds own 36.47% of the company’s stock.

Several equities research analysts have issued reports on ABEO shares. SVB Leerink restated a “buy” rating on shares of Abeona Therapeutics in a report on Monday, March 29th. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, February 19th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Abeona Therapeutics in a research note on Wednesday, April 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $4.71.

Shares of ABEO opened at $1.71 on Wednesday. The firm has a market capitalization of $168.86 million, a price-to-earnings ratio of -1.64 and a beta of 1.69. The stock’s fifty day moving average is $1.78 and its 200-day moving average is $1.80. Abeona Therapeutics has a one year low of $0.99 and a one year high of $3.79.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Tuesday, March 23rd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.07). The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.55 million. On average, research analysts expect that Abeona Therapeutics will post -0.46 earnings per share for the current fiscal year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: How a Strangle Strategy is different from a Straddle Strategy

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.